AJZ Engineering to re-equip Russian cancer centre:
This article was originally published in Clinica
German company AJZ Engineering has been contracted to modernise and equip the "Blochin" Oncology Research Centre at the Russian Academy of Medical Sciences in Moscow. The contract is worth E60 million ($50 million) and involves re-equipping the surgery centre, the bone marrow transplant centre and the central sterilisation facility, and modernising parts of the centre's radiation therapy and laboratory diagnostic units. The project is expected to take two years. Jena-based AJZ Engineering will include a number of companies from eastern Germany in the project, mostly from Thuringia. The company co-operated with Siemens Medical Solutions to modernise the radiation therapy and imaging diagnostics units. AJZ Engineering is a joint venture of Analytik Jena and Carl Zeiss Jena.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.